Stocks to Watch: Cerevel Therapeutics, Nogin, Braze

Dow Jones2023-12-07

By Ben Glickman

Cerevel Therapeutics will be acquired by AbbVie for about $8.7 billion. The pharmaceutical giant announced it would buy the neuroscience-drug maker for $45 a share, representing a premium of 22% based on the Wednesday closing price of $36.93. Shares rise 16%, to $42.69, after-hours.

Nogin is entering Chapter 11 bankruptcy proceedings, with backing by B. Riley Financial. The e-commerce technology company said there would be no interruptions to service as it financially restructures, which is meant to add stability and allow for future growth. Shares rise 12%, to 20.4 cents, after-hours.

Braze's revenue surged 33% in the fiscal third quarter, topping analysts' estimates and helping the cloud-software company's loss narrow. The company also increased its full-year guidance for revenue and said it expects a narrower loss than previously forecast. Shares rise 12%, to $63, after-hours.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 06, 2023 18:21 ET (23:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2389255067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-12-07 07:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2389255067","market":"nz","top_or_hot":-1,"title":"Stocks to Watch: Cerevel Therapeutics, Nogin, Braze","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Cerevel Therapeutics will be acquired by AbbVie for about $8.7 billion. The pharmaceutical giant announced it would buy the neuroscience-drug maker for $45 a share, representing a premium of 22% based on the Wednesday closing price of $36.93. Shares rise 16%, to $42.69, after-hours. \n</p>\n<p>\n  Nogin is entering Chapter 11 bankruptcy proceedings, with backing by B. Riley Financial. The e-commerce technology company said there would be no interruptions to service as it financially restructures, which is meant to add stability and allow for future growth. Shares rise 12%, to 20.4 cents, after-hours. \n</p>\n<p>\n  Braze's revenue surged 33% in the fiscal third quarter, topping analysts' estimates and helping the cloud-software company's loss narrow. The company also increased its full-year guidance for revenue and said it expects a narrower loss than previously forecast. Shares rise 12%, to $63, after-hours. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 06, 2023 18:21 ET (23:21 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Cerevel Therapeutics, Nogin, Braze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Cerevel Therapeutics, Nogin, Braze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-07 07:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Ben Glickman \n\n\n \n\n\n  Cerevel Therapeutics will be acquired by AbbVie for about $8.7 billion. The pharmaceutical giant announced it would buy the neuroscience-drug maker for $45 a share, ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2389255067","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2389255067","pubTimestamp":1701904860,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Cerevel Therapeutics will be acquired by AbbVie for about $8.7 billion. The pharmaceutical giant announced it would buy the neuroscience-drug maker for $45 a share, representing a premium of 22% based on the Wednesday closing price of $36.93. Shares rise 16%, to $42.69, after-hours.Nogin is entering Chapter 11 bankruptcy proceedings, with backing by B. Riley Financial. The e-commerce technology company said there would be no interruptions to service as it financially restructures, which is meant to add stability and allow for future growth. Shares rise 12%, to 20.4 cents, after-hours.Braze's revenue surged 33% in the fiscal third quarter, topping analysts' estimates and helping the cloud-software company's loss narrow. The company also increased its full-year guidance for revenue and said it expects a narrower loss than previously forecast. Shares rise 12%, to $63, after-hours.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4023":"应用软件","BK4122":"互联网与直销零售","BK4220":"综合零售","BRZE":"Braze, Inc.","CERE":"Cerevel Therapeutics Holdings, Inc."},"translate_title":"值得关注的股票：Cerevel Therapeutics，Nogin，Braze","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRZE":1,"CERE":0.9,"NOGN":0.9},"content_text":"By Ben Glickman \n\n\n \n\n\n  Cerevel Therapeutics will be acquired by AbbVie for about $8.7 billion. The pharmaceutical giant announced it would buy the neuroscience-drug maker for $45 a share, representing a premium of 22% based on the Wednesday closing price of $36.93. Shares rise 16%, to $42.69, after-hours. \n\n\n  Nogin is entering Chapter 11 bankruptcy proceedings, with backing by B. Riley Financial. The e-commerce technology company said there would be no interruptions to service as it financially restructures, which is meant to add stability and allow for future growth. Shares rise 12%, to 20.4 cents, after-hours. \n\n\n  Braze's revenue surged 33% in the fiscal third quarter, topping analysts' estimates and helping the cloud-software company's loss narrow. The company also increased its full-year guidance for revenue and said it expects a narrower loss than previously forecast. Shares rise 12%, to $63, after-hours. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2023 18:21 ET (23:21 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2389255067"}